Breaking Finance News

Peel Hunt disclosed Clinigen Group (LON:CLIN), boosting its price target to 1,200.00GBX earlier today

Reporting a potential upside of 0%, Peel Hunt upped the price target of Clinigen Group (LON:CLIN) to 1,200.00GBX

On 5/22/2017, Stifel released a statement about Clinigen Group (LON:CLIN) maintained the target price at 970.00GBX that suggested an upside of 0.13%.

Having a price of 0.00GBX, Clinigen Group (LON:CLIN) traded -3.08% lower on the day. With the last stock price down 12.96% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.05% over the same period. CLIN has recorded a 50-day average of 936.59GBX and a two hundred day average of 862.23GBX. Trade Volume was down over the average, with 212,443 shares of CLIN changing hands under the typical 269,050

Recent Performance Chart

Clinigen Group (LON:CLIN)

Clinigen Group has PE ratio of 77.92 with a one year low of 615.11GBX and a one year high of 1,033.00GBX and has a market capitalization of 0 GBX.

A total of 5 brokerages have issued a ratings update on Clinigen Group. Three brokerages rating the company a strong buy, two brokerages rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of 850.00GBX.

General Company Details For Clinigen Group (LON:CLIN)

Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company's principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.